Drug intelligence / Profile preview

RBI-8000

Development stage: Unknown
Lead developer: Replicate Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

**RBI-8000** is a self-replicating RNA (srRNA) therapeutic in early development as a pan-inflammasome inhibitor targeting IL-1 and IL-18 pathways for inflammatory and autoimmune diseases. Developed by Replicate Bioscience, a Duke University spinout leveraging synthetic biology for RNA treatments, it utilizes RNA interference to silence key inflammasome components, enabling prolonged protein suppression at lower doses compared to conventional RNA therapies. The program remains in discovery/preclinical stages with potential broad applications in autoimmunity.[1][6][10][12]

Targets

IL18 (Interleukin-18)Interleukin-1 beta messenger RNA

Beyond the preview

Go deeper on RBI-8000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBI-8000.

Explore the full profile